Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | CHAT | P28329 | 6/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873129 | 1.00 | KDM4E (0.52) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL30747848 | 0.83 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDPTGS1PTGS2 | |
| SCHEMBL29673969 | 0.81 | CHAT (0.49) | KDM4EALDH1A1HPGDPTGS1PTGS2 | |
| SCHEMBL318015 | 0.81 | CHAT (0.49) | KDM4EALDH1A1HPGDPTGS1PTGS2 | |
| SCHEMBL318014 | 0.81 | CHAT (0.49) | KDM4EALDH1A1HPGDPTGS1PTGS2 | |
| SCHEMBL10706687 | 0.80 | CHAT (0.62) | KDM4EALDH1A1PTGS1PTGS2CHAT | |
| SCHEMBL10706694 | 0.80 | CHAT (0.62) | KDM4EALDH1A1PTGS1PTGS2CHAT | |
| SCHEMBL10706700 | 0.80 | CHAT (0.62) | KDM4EALDH1A1PTGS1PTGS2CHAT | |
| SCHEMBL14279418 | 0.80 | RAB9A (0.59) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3162895 | 0.80 | RAB9A (0.59) | KDM4EALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130287700-A1 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM | KLINIKUM DARMSTADT GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| EP-2619591-A2 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM | Technische Universität Darmstadt (DE) | 2013-07-31 | — | — | EP | disclosed |
| EP-2619590-A2 | COMPOUNDS FOR DIAGNOSING NEURODEGENERATIVE DISEASES AT THE RETINA | Technische Universität Darmstadt (DE) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012041292-A2 | COMPOUNDS FOR DIAGNOSING NEURODEGENERATIVE DISEASES AT THE RETINA | KLINIKUM DARMSTADT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012037928-A2 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM | KLINIKUM DARMSTADT GMBH (DE) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287700-A1 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM | SNCA, MAPT, TARDBP | KDM4E 4621/4885ALDH1A1 1165/4885HPGD 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.